Ondine Biomedical Inc. (OBI.L)

6.60 +1.47 (+28.78%) At close: 04:45PM BST

Ondine Biomedical Inc.

1100 Melville Street
Suite 888
Vancouver, BC V6E 4A6
Canada
604-669-0555
https://www.ondinebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA	Founder, CEO & Executive Director	500.71k	N/A	N/A
Dr. Nicolas G. Loebel Ph.D.	President, CTO & Executive Director	584.98k	N/A	N/A
Dr. Simon Sinclair Ph.D.	Chief Medical Officer & Director	72.96k	N/A	1972
Mr. Kwong Choo CPA, CIMA	Interim Chief Financial Officer	N/A	N/A	N/A
Mr. William Kanz	Senior VP of Engineering & Operations	N/A	N/A	N/A
Angelika Vance	Vice President of Corporate Communications	N/A	N/A	N/A
Mr. Matt Ross	Vice President of Sales & Marketing	N/A	N/A	N/A
Ms. Elaine Lei CPA	Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Corporate governance

Ondine Biomedical Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.